- Home
- TBPH vs BIT Comparison
TBPH vs BIT Comparison
Compare TBPH & BIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBPH
- BIT
- Stock Information
- Founded
- TBPH 2013
- BIT 2013
- Country
- TBPH United States
- BIT United States
- Employees
- TBPH N/A
- BIT N/A
- Industry
- TBPH Biotechnology: Pharmaceutical Preparations
- BIT Trusts Except Educational Religious and Charitable
- Sector
- TBPH Health Care
- BIT Finance
- Exchange
- TBPH Nasdaq
- BIT Nasdaq
- Market Cap
- TBPH 536.5M
- BIT 597.5M
- IPO Year
- TBPH N/A
- BIT N/A
- Fundamental
- Price
- TBPH $11.15
- BIT $14.64
- Analyst Decision
- TBPH Strong Buy
- BIT
- Analyst Count
- TBPH 5
- BIT 0
- Target Price
- TBPH $16.60
- BIT N/A
- AVG Volume (30 Days)
- TBPH 245.1K
- BIT 92.4K
- Earning Date
- TBPH 08-04-2025
- BIT 01-01-0001
- Dividend Yield
- TBPH N/A
- BIT 9.36%
- EPS Growth
- TBPH N/A
- BIT N/A
- EPS
- TBPH N/A
- BIT N/A
- Revenue
- TBPH $65,266,000.00
- BIT N/A
- Revenue This Year
- TBPH $43.18
- BIT N/A
- Revenue Next Year
- TBPH N/A
- BIT N/A
- P/E Ratio
- TBPH N/A
- BIT N/A
- Revenue Growth
- TBPH 6.11
- BIT N/A
- 52 Week Low
- TBPH $7.44
- BIT $13.65
- 52 Week High
- TBPH $11.82
- BIT $15.97
- Technical
- Relative Strength Index (RSI)
- TBPH 62.38
- BIT 69.88
- Support Level
- TBPH $10.87
- BIT $14.53
- Resistance Level
- TBPH $11.44
- BIT $14.72
- Average True Range (ATR)
- TBPH 0.29
- BIT 0.07
- MACD
- TBPH -0.00
- BIT 0.02
- Stochastic Oscillator
- TBPH 71.92
- BIT 79.49
About TBPH Theravance Biopharma Inc.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
About BIT BlackRock Multi-Sector Income Trust of Beneficial Interest
BlackRock Multi-Sector Income Trust is a closed-end investment management company. It invests on behalf of its clients. The fund's primary investment objective is to provide a high level of current income, with a secondary objective of capital appreciation. The company seeks to achieve its investment objectives by investing, under normal market conditions, a majority of its assets in loan and debt instruments and other investments with similar economic characteristics. Its portfolio consists of Corporate Bonds, Asset-Backed Securities, Preferred Securities, and others.